Can cytology replace tumor tissue in determining somatic mutations of BRCA 1/2 genes in patients with epithelial carcinoma of ovaries, fallopian tubes or peritoneal serous carcinoma?
Not Applicable
Completed
- Conditions
- Malignant ascites in patients with high grade serous cancer of ovaries, fallopian tubes or peritoneal serous cancerCancer
- Registration Number
- ISRCTN42408038
- Lead Sponsor
- Institute of Oncology Ljubljana
- Brief Summary
2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/30940100 results 2022 Other publications in https://pubmed.ncbi.nlm.nih.gov/35326583/ (added 03/01/2023) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/39178525/ (added 27/08/2024)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
1. Malignant ascites determined by cytology
2. Histology proven high-grade serous cancer of ovaries, fallopian tubes or serous peritoneal cancer
Exclusion Criteria
1. Non-malignant ascites
2. Histology other than high-grade serous cancer of ovaries, fallopian tubes or serous peritoneal cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determination of somatic BRCA 1/2 gene mutations from cytology material provided from malignant ascites and tumor tissue - 100% correlation expected, proper method to be identified.
- Secondary Outcome Measures
Name Time Method